Pfizer Inc (PFE)

[DewDiligence]

PFE’s Marstacimab reduces bleeding events by 35% compared to prophylactic factor-replacement therapy in hemophilia A/B patients without inhibitors:

https://finance.yahoo.com/news/pfizer-announces-positive-marstacimab-results-104500742.html

Marstacimab is a tissue factor pathway inhibitor (TFPI), thereby working on the extrinsic pathway of the coagulation cascade (the opposite side of the cascade from FXII and FIX).

The data released today are for the subset of patents in an open-label phase-3 BASIS trial who had hemophilia without inhibitors, where the comparator was either prophylactic FVII/FIX therapy or on-demand FVIII/FIX therapy. Compared to the prophylactic control arm, Marstacimab reduced bleeds by 35% (p=.038); compared to the on-demand control arm, Marstacimab reduced bleeds by 92% (p<0.00001).

Data for the subset of patients with inhibitors are expected in 2024. For patients with inhibitors, the comparator is “bypass” therapy (FEIBA or rFVIIa).